St2 antigen binding proteins
US-2024368292-A1 · Nov 7, 2024 · US
ST2L antagonists and methods of use
US9951137B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9951137-B2 |
| Application number | US-201514939624-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 12, 2015 |
| Priority date | Apr 30, 2012 |
| Publication date | Apr 24, 2018 |
| Grant date | Apr 24, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
First claim
Opening claim text (preview).
We claim: 1. A method of inhibiting IL-33-induced GM-CSF release from primary human lung mast cells in a patient, comprising administrating a therapeutically effective amount of an isolated antibody antagonist or fragment thereof that specifically binds Domain I (SEQ ID NO: 9) of human ST2L to a patient in need thereof for a time sufficient to inhibit the IL-33-induced GM-CSF release from primary human lung mast cells, wherein the antibody comprises the heavy chain complementarity determining regions (HCDR1, HCDR2, HCDR3) and the light chain complementarity determining regions (LCDR1, LCDR2, LCDR3) of SEQ ID NOs: 97, 114, 84, 130, 90, and 134, respectively. 2. The method of claim 1 , wherein the antibody antagonist blocks IL-33/ST2L interaction. 3. The method of claim 2 , wherein the antibody antagonist comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: (a) the VH is derived from human IGHV3-23 framework sequence (SEQ ID NO: 158); and (b) the VL is derived from human IGKV3-11 (L6) framework sequence (SEQ ID NO: 159). 4. The method of claim 3 , wherein the antibody antagonist is of IgG1, IgG2, IgG3, or IgG4 isotype. 5. The method of claim 4 , wherein the antibody antagonist comprises the VH of SEQ ID NO: 191 and the VL of SEQ ID NO: 209. 6. The method of claim 1 , wherein the antibody antagonist is a human or humanized antibody.
Assignees
Inventors
Classifications
Drugs for disorders of the respiratory system · CPC title
comprising antibodies · CPC title
Complementarity determining region [CDR] · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9951137B2 cover?
- The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2866. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).